Proposition 14: First CEO of California Stem Cell Agency Says $5.5 Billion Stem Cell Measure Not Needed
By David Jensen,
California Stem Cell Report
| 10. 26. 2020
The first president of the California stem cell agency, Zach Hall, says that he would vote against the $5.5 billion ballot measure to save the research enterprise from financial extinction if he still lived in California.
Hall, now retired and living in Wyoming, says a justification for agency existed in 2004 when it was created by voters via another ballot measure, the $3 billion Proposition 71.
But, according to the new book, "California's Great Stem Cell Experiment," Hall says "that the rationale and need are not so evident today for a state-supported agency dedicated to stem cell research."
The creation of induced pluripotent stem cells has largely supplanted the use of cells derived from embryos, Hall said. The Bush Administration restrictions on human embryonic stem cell research were major drivers for Proposition 71, but those have now been lifted.
Hall said that the National Institutes of Health could likely support most of the stem cell work that is now backed by CIRM.
Proposition 14, the $5.5 billion ballot initiative, would refill the stem cell agency's coffers. The program...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
